Earnings call briefSecond-quarter 2026
Vertex says it now expects 2026 revenue of $13.1 billion to $13.2 billion
Vertex said its 2026 revenue range does not yet reflect the pending Crinetics acquisition, which it expects to close in the third quarter.
GetSignal Vertex Pharmaceuticals VRTX
On its second-quarter call, Vertex Pharmaceuticals said it is raising its full-year 2026 total revenue range. The company said it now expects combined non-GAAP operating expenses at the high end of its $5.65 billion to $5.75 billion range, which it reiterated. It also said it continues to expect revenue of $500 million or greater from non-CF products.
Quotes from the call
“...we are raising our full year 2026 total revenue guidance to a range of $13.1 billion to $13.2 billion...”
Key facts from the call
- Full-year 2026 total revenue outlook
- $13.1 billion to $13.2 billion
- 2026 non-GAAP operating expense range
- $5.65 billion to $5.75 billion, now expected at the high end
- Expected 2026 non-CF revenue
- $500 million or greater
- Crinetics acquisition expected close
- Third quarter 2026
Source: Vertex Pharmaceuticals' second-quarter 2026 earnings call, August 3, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.
More earnings call briefs
- Vertex Pharmaceuticals lifts 2026 non-GAAP expense outlook to about $6 billion
VRTX Vertex Pharmaceuticals Q3 2026 call
- Constellation Energy expects nuclear uprate costs of about $4.3 billion
CEG Constellation Energy Q3 2026 call
- Howard Hughes Holdings says its insurance ambition is a return on equity in excess of 20%
HHH Howard Hughes Holdings Q3 2026 call
- Brookfield Asset Management now sees 2026 earnings modestly below early view
BAM Brookfield Asset Management Q3 2026 call
- Enbridge says it expects 2026 results at the midpoint of its guidance range
ENB Enbridge Q3 2026 call
